Adam M. Spivak,
MD
Languages Spoken: English
Dr. Spivak joined the Division of Infectious Diseases at the University of Utah in the fall of 2011 after completing residency and fellowship training at Johns Hopkins University School of Medicine. He cares for HIV patients as a member of the Clinic 1A staff at the University of Utah Hospital and attends on the inpatient Infectious Diseases consult service at both the University and VA Hospitals.
Clinical Locations
University Hospital
Infectious Diseases, Clinic 1A801-585-2031
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor Pathology - Adjunct Assistant Professor |
| Academic Divisions | Infectious Diseases Microbiology and Immunology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Infectious Disease) |
Dr. Spivak joined the Division of Infectious Diseases in October 2011 after completing Infectious Diseases fellowship training at Johns Hopkins University School of Medicine. His primary focus is on translational research exploring HIV persistence and strategies for viral eradication. At the University of Utah, Dr. Spivak spends the majority of his time in a basic science laboratory working with his scientific mentor Dr. Vicente Planelles in the Department of Pathology. Working with members of the Planelles lab, he conducts ongoing research into the nature of HIV persistence. He cares for HIV patients as a member of the Clinic 1A staff at the University of Utah Hospital and attends on the inpatient Infectious Diseases consult service at both the University and VA Hospitals.
During fellowship, Dr. Spivak spent three years in the laboratory of Dr. Robert Siliciano where he studied cellular reservoirs of HIV and helped to run a pilot clinical trial of a novel HIV eradication strategy. In May 2011, Dr. Spivak was awarded a Bill and Melinda Gates Foundation Grand Challenges Explorations Grant for a research proposal describing an in vitro screening assay to identify compounds able to selectively induce apoptosis in HIV infected cells. In 2016 Dr. Spivak was selected by the Doris Duke Charitable Foundation to receive a Clinical Scientist Development Award that supports his current research developing novel strategies to eliminate the HIV latent reservoir.
Academic Locations
School of Medicine
801-581-8812
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor Pathology - Adjunct Assistant Professor |
| Academic Divisions | Infectious Diseases Microbiology and Immunology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Infectious Disease) |
Education History
| Fellowship | Johns Hopkins University School of Medicine Infectious Diseases Fellow |
| Chief Resident | Johns Hopkins University School of Medicine Internal Medicine Chief Resident |
| Residency | Johns Hopkins University School of Medicine Internal Medicine Resident |
| Internship | Johns Hopkins University School of Medicine Internal Medicine Intern |
| Professional Medical | University of Maryland School of Medicine Medicine M.D. |
| Undergraduate | Princeton University English Literature A.B. |
Publications - Journal Articles
Journal Article
- Spivak AM, Planelles V (2017). Novel Latency Reversal Agents for HIV-1 Cure.LID - 10.1146/annurev-med-052716-031710 [doi]. (Epub ahead of print) Annu Rev Med.
- Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V (2017). Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Rep, 18(5), 1324-1334.
- Spivak AM, Larragoite ET, Coletti ML, Macedo AB, Martins LJ, Bosque A, Planelles V (2016). Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo. Retrovirology, 13(1), 88.
- Garrido C, Spivak AM, Soriano-Sarabia N, Checkley MA, Barker E, Karn J, Planelles V, Margolis DM (2016). HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. Front Immunol, 7, 356.
- Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Typsteen W, Bosque A, Vanderkerckhove L, Planelles V (2016). Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. AIDS Res Hum Retroviruses, 32(2), 187-93.
- Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V (2015). Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother, 59(10), 5984-91.
- Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, Martins LJ, Konig R, Simon V, Bosque A, Fernandez-Sesma A, Cosford ND, Bushman FD, Young JA, Planelles V, Chanda SK (2015). BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe, 18(3), 345-53.
- Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG (2014). A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis, 58(6), 883-90.
- Barber AE, Norton JP, Spivak AM, Mulvey MA (2013). Urinary tract infections: current and emerging management strategies. Clin Infect Dis, 57(5), 719-24.
- Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA, Spivak AM, Siliciano RF, Stivers JT (2013). Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc Natl Acad Sci U S A, 110(6), E448-57.
- Spivak AM, Salgado M, Rabi SA, OConnell KA, Blankson JN (2011). Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J Virol, 85(19), 10399-403.
- Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, Siliciano RF (2011). Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses, 27(7), 759-61.
- Gaillard S, Dinoso JB, Marsh JA, DeZern AE, OConnell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson JN (2011). Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. J Clin Virol, 51(3), 195-8.
- Spivak AM, Brennan TP, OConnell KA, Sydnor E, Williams TM, Siliciano RF, Gallant JE, Blankson JN (2010). A case of seronegative HIV-1 infection. J Infect Dis, 201(3), 341-5.
Review
- Spivak AM, Planelles V (2016). HIV-1 Eradication: Early Trials (and Tribulations). [Review]. Trends Mol Med, 22(1), 10-27.
- Spivak AM, Sydnor ER, Blankson JN, Gallant JE (2010). Seronegative HIV-1 infection: a review of the literature. [Review]. AIDS, 24(10), 1407-14.
- Pradilla G, Nagahama Y, Spivak AM, Bydon A, Rigamonti D (2010). Spinal epidural abscess: current diagnosis and management. [Review]. Current Infectious Disease Reports, 12(6), 484-91.
Letter
Poster
- Spivak AM, Bosque A, Planelles V (2014). An In Vitro Compound Screen for Selective Apoptosis Induction In HIV-1 Infected Resting CD4+ T Cells. Poster session presented at 2014 Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA.
- Spivak AM, Andrade A, Hoh R, Bacchetti P, Eisele E, Buckheit III R, Lai J, Siliciano J, Siliciano R, Deeks S (2012). Safety and Feasibility of Using Disulfiram to Enhance HIV Transcription among Long-term ARV-treated Adults: Preliminary Results from a Pilot Study. Poster session presented at 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
- Spivak AM, Gaillard S, Dinoso J, Marsh J, Blankson J (2011). Sustained Elite Suppression of Replication Competent HIV-1 in a Patient Treated with Rituximab Based Chemotherapy. [Abstract 291]. Poster session presented at 18th CROI, Boston, MA.
- Spivak AM, Reza A, McMahon M, Sedaghat A, Siliciano RF (2009). Understanding Decay of Viremia in Patients on Raltegravir. . [Abstract 552]. Poster session presented at 16th CROI, Montreal, Canada.